CN117843645A - 一种pde9抑制剂的一水合物和结晶形态 - Google Patents

一种pde9抑制剂的一水合物和结晶形态 Download PDF

Info

Publication number
CN117843645A
CN117843645A CN202311855412.9A CN202311855412A CN117843645A CN 117843645 A CN117843645 A CN 117843645A CN 202311855412 A CN202311855412 A CN 202311855412A CN 117843645 A CN117843645 A CN 117843645A
Authority
CN
China
Prior art keywords
crystalline form
monohydrate
monohydrate crystalline
compound
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311855412.9A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊妮·巴塔
马特乌什·皮塔克
亚当·罗斯·帕特森
塞缪尔·亚历山大·斯特拉特福德
伊万娜·索瓦戈
徐军
周鹏
魏昊娟
戴匡初
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of CN117843645A publication Critical patent/CN117843645A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN202311855412.9A 2018-05-25 2019-05-23 一种pde9抑制剂的一水合物和结晶形态 Pending CN117843645A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862676381P 2018-05-25 2018-05-25
US62/676,381 2018-05-25
US201962788323P 2019-01-04 2019-01-04
US62/788,323 2019-01-04
CN201980049524.0A CN112469413B (zh) 2018-05-25 2019-05-23 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态
PCT/US2019/033835 WO2019226944A1 (en) 2018-05-25 2019-05-23 Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980049524.0A Division CN112469413B (zh) 2018-05-25 2019-05-23 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态

Publications (1)

Publication Number Publication Date
CN117843645A true CN117843645A (zh) 2024-04-09

Family

ID=68617192

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311855412.9A Pending CN117843645A (zh) 2018-05-25 2019-05-23 一种pde9抑制剂的一水合物和结晶形态
CN201980049524.0A Active CN112469413B (zh) 2018-05-25 2019-05-23 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980049524.0A Active CN112469413B (zh) 2018-05-25 2019-05-23 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态

Country Status (22)

Country Link
US (2) US12006319B2 (https=)
EP (2) EP3801526B1 (https=)
JP (2) JP7818900B2 (https=)
KR (1) KR102923255B1 (https=)
CN (2) CN117843645A (https=)
AU (1) AU2019275075B2 (https=)
BR (2) BR112020024019A2 (https=)
CA (1) CA3100988A1 (https=)
DK (1) DK3801526T3 (https=)
ES (1) ES2975792T3 (https=)
FI (1) FI3801526T3 (https=)
HR (1) HRP20240363T1 (https=)
HU (1) HUE065709T2 (https=)
IL (1) IL278875A (https=)
LT (1) LT3801526T (https=)
MA (1) MA52792A (https=)
MX (2) MX2020012636A (https=)
PL (1) PL3801526T3 (https=)
PT (1) PT3801526T (https=)
SI (1) SI3801526T1 (https=)
WO (1) WO2019226944A1 (https=)
ZA (1) ZA202401459B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
EP3965768A1 (en) * 2019-05-07 2022-03-16 Imara Inc. Pde9 inhibitors for treating thalassemia
US20240025904A1 (en) * 2020-10-27 2024-01-25 Cardurion Pharmaceuticals, Inc. Pde9 inhibitors for treating cardiac failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810187A (zh) * 2015-07-07 2018-03-16 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (https=) 1972-06-16 1978-05-11
JPS5318013B2 (https=) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
AU2989695A (en) 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
JPH10507179A (ja) 1994-10-13 1998-07-14 ペプチド テクノロジー リミテッド 修飾ポリ不飽和脂肪酸
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6531150B1 (en) 1997-10-30 2003-03-11 Morishita Jintan Co., Ltd. Encapsulated unsaturated fatty acid substance and method for producing the same
CA2395558C (en) 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
IL144156A0 (en) 1999-01-20 2002-05-23 Dresden Arzneimittel Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
AU5319499A (en) 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
EP1294658B1 (en) 2000-06-28 2005-03-02 ZAMBON GROUP S.p.A. Process for the preparation of nitroalkenes
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
DE20221679U1 (de) 2001-03-02 2006-11-23 Debiopharm S.A. Vorrichtung zur Konditionierung einer Oxaliplatinlösung
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
EP1407767A4 (en) 2001-06-18 2007-01-24 Yamada Sachiko AGONIST MEDICINAL PREPARATIONS PPAR $ G (G)
EP1418876A4 (en) 2001-08-17 2007-07-11 Univ Pittsburgh ADMINISTRATION OF OSTRADIOL METABOLITES FOR THE TREATMENT OR PREVENTION OF ADIPOSITAS, METABOLIC SYNDROME, DIABETES AND VASCULAR AND KIDNEY DISEASES
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
JP2005508978A (ja) 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
US20030166716A1 (en) 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
CA2875522A1 (en) 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
EP2384750A1 (en) 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
WO2004037311A2 (en) 2002-10-21 2004-05-06 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
WO2005041972A1 (en) 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US7776916B2 (en) 2004-04-28 2010-08-17 The Uab Research Foundation Nitrated lipids and methods of making and using thereof
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1772149A1 (en) 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
BRPI0516803A (pt) 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
WO2006058250A2 (en) 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
AU2011202664B2 (en) 2004-12-08 2012-04-05 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
WO2006086727A2 (en) 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2008008767A2 (en) 2006-07-14 2008-01-17 Cedars-Sinai Medical Center Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
MX2009000657A (es) 2006-07-19 2009-05-28 Resolvyx Pharmaceuticals Inc Composiciones y metodos para el tratamiento de mucositis.
EP2123801A4 (en) 2006-09-08 2011-01-19 Tokuyama Corp METHOD AND DEVICE FOR PREPARING GROUP III NITRIDE
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
WO2008103753A2 (en) 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
CA2699483A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
EA017064B1 (ru) 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
WO2009129495A1 (en) 2008-04-18 2009-10-22 The University Of Utah Research Foundation Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
JP2011519373A (ja) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
EP2320903B1 (en) 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US8937194B2 (en) 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
US8933255B2 (en) 2008-12-31 2015-01-13 Nitromega Corp. Nutraceuticals containing nitro fatty acids
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
JP2013500275A (ja) 2009-07-29 2013-01-07 フェノメノーム ディスカバリーズ インク ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用
EP3045167A1 (en) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Keto fatty acids as anti-inflammatory agents
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
CA2777455A1 (en) 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Novel 1,3-oxazolidine compounds and their use as renin inhibitors
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
KR20130054249A (ko) 2010-03-15 2013-05-24 울리히 디에츠 공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도
EP2568826A4 (en) 2010-05-13 2014-03-26 Nitromega Corp NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE
US20110319325A1 (en) 2010-06-28 2011-12-29 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
JO3116B1 (ar) 2011-10-07 2017-09-20 Eisai R&D Man Co Ltd مشتق بيرازولوكينولين كمثبطات ل pde9
BR112015007731B1 (pt) 2011-10-10 2022-05-31 H. Lundbeck A/S Composto, composição farmacêutica que o compreende e uso do mesmo
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
ES2681027T3 (es) 2012-02-01 2018-09-11 City Of Hope Inhibidores de la ribonucleótida reductasa y métodos de uso
WO2013116753A1 (en) 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
US10435367B2 (en) 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
JP6463266B2 (ja) 2012-08-31 2019-01-30 タリス バイオメディカル エルエルシー 膀胱癌の治療のためのオキサリプラチンを含む薬物送達システム及び方法
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
WO2014169137A1 (en) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
CN105339006A (zh) 2013-05-10 2016-02-17 尼特罗米加公司 含有脂肪酸和亚硝酸盐的营养或膳食补充剂
US20150051283A1 (en) 2013-06-14 2015-02-19 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
WO2015185499A1 (en) 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
WO2016161285A1 (en) 2015-04-02 2016-10-06 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
WO2017059451A1 (en) 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
MX376974B (es) 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
MX2018016127A (es) 2016-07-06 2019-05-30 Imara Inc Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
CN115746003B (zh) 2017-05-26 2024-08-09 卡都瑞恩医药公司 制备和使用pde9抑制剂的方法
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
EP3946348A4 (en) 2019-04-05 2023-08-02 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
EP3965768A1 (en) 2019-05-07 2022-03-16 Imara Inc. Pde9 inhibitors for treating thalassemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810187A (zh) * 2015-07-07 2018-03-16 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂

Also Published As

Publication number Publication date
KR102923255B1 (ko) 2026-02-04
MA52792A (fr) 2021-04-14
CA3100988A1 (en) 2019-11-28
JP7818900B2 (ja) 2026-02-24
HRP20240363T1 (hr) 2024-06-07
US20210107911A1 (en) 2021-04-15
EP4349403B1 (en) 2026-05-06
JP2024095561A (ja) 2024-07-10
EP4349403A2 (en) 2024-04-10
EP3801526B1 (en) 2023-12-27
BR112020024019A2 (pt) 2021-02-23
AU2019275075A1 (en) 2021-01-14
ZA202401459B (en) 2025-07-30
SI3801526T1 (sl) 2024-05-31
AU2019275075B2 (en) 2024-11-28
WO2019226944A1 (en) 2019-11-28
DK3801526T3 (da) 2024-03-25
EP3801526A1 (en) 2021-04-14
EP3801526A4 (en) 2022-04-06
LT3801526T (lt) 2024-04-10
PT3801526T (pt) 2024-03-26
MX2020012636A (es) 2021-01-29
JP2021526134A (ja) 2021-09-30
BR122023022641A2 (pt) 2024-02-20
EP4349403A3 (en) 2024-06-05
CN112469413B (zh) 2024-01-12
ES2975792T3 (es) 2024-07-15
HUE065709T2 (hu) 2024-06-28
IL278875A (en) 2021-01-31
PL3801526T3 (pl) 2024-08-05
US12466832B2 (en) 2025-11-11
MX2023009562A (es) 2023-08-22
US12006319B2 (en) 2024-06-11
KR20210014662A (ko) 2021-02-09
FI3801526T3 (fi) 2024-03-20
US20240199627A1 (en) 2024-06-20
CN112469413A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
CN117843645A (zh) 一种pde9抑制剂的一水合物和结晶形态
JP5008777B2 (ja) （Ｒ）−５−［３−クロロ−４−（２，３−ジヒドロキシ−プロポキシ）−ベンズ［Ｚ］イリデン］−２−（［Ｚ］−プロピルイミノ）−３−ｏ−トリル−チアゾリジン−４−オンの結晶
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
DK2273994T3 (en) PHARMACEUTICAL FORMS OF A MEDICINE
JP2017193561A (ja) ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態
JP2013529224A (ja) 結晶性エザチオスタット塩酸塩非溶媒和物
US12559478B2 (en) Co-crystal forms of selinexor
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
HK40111321A (en) Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
US20220251091A1 (en) Amorphous umbralisib monotosylate
HK40046993B (en) Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
HK40046993A (en) Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
EA045017B1 (ru) МОНОГИДРАТНАЯ И КРИСТАЛЛИЧЕСКАЯ ФОРМЫ 6-[(3S,4S)-4-МЕТИЛ-1-(ПИРИМИДИН-2-ИЛМЕТИЛ)ПИРРОЛИДИН-3-ИЛ]-3-ТЕТРАГИДРОПИРАН-4-ИЛ-7H-ИМИДАЗО[1,5-а]ПИРАЗИН-8-ОНА
HK40074778B (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
HK1157679A (zh) 藥學試劑的固體形式

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240605

Address after: Massachusetts, USA

Applicant after: Cadurion Pharmaceuticals

Country or region after: U.S.A.

Address before: Massachusetts, USA

Applicant before: IMARA Inc.

Country or region before: U.S.A.

TA01 Transfer of patent application right